Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics

威斯康星州和新泽西州精密实验治疗联盟

基本信息

批准号：
8725876
负责人：
ROBERT S. DIPAOLA
金额：
$ 85万
依托单位：
RBHS -CANCER INSTITUTE OF NEW JERSEY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-19 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8725876
关键词：
Antineoplastic Agents Area Biological Markers Cancer Center Cancer Institute of New Jersey Cancer Therapy Evaluation Program Cells Clinical Clinical Research Clinical Trials Clinical Trials Network Collaborations Comprehensive Cancer Center Conduct Clinical Trials DNA Repository Development Drug Kinetics Funding Future Genomics Goals Grant Image Image Analysis Institutes Institution Laboratories Lead Leadership Mission Modeling Monitor NCI Center for Cancer Research NCI-Designated Cancer Center New Jersey Outcome Pathology Patients Peer Review Pharmacodynamics Pharmacogenomics Pharmacologic Substance Phase Protocols documentation Recording of previous events Research Research Infrastructure Research Personnel Resource Sharing Resources Science Sequence Analysis Site Systems Biology Therapeutic Therapeutic Clinical Trial Therapeutic Studies Therapy Clinical Trials Tissues Toxic effect Training Translating Translational Research Universities Wisconsin digital expectation functional genomics improved innovation member multidisciplinary novel strategies programs response tumor working group

项目摘要

DESCRIPTION (provided by applicant): As two NCI-designated comprehensive cancer centers that were collaborative as prior UOl sites, the University of Wisconsin Carbone Cancer Center (UWCCC) and Rutgers Cancer Institute of New Jersey (CINJ) have proven leadership, a robust infrastructure, and a strong record of conducting clinical trials collaboratively. UWCCC and CINJ have, therefore, formed the Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics (WIN-Alliance) with a mission to develop and evaluate innovative early phase experimental therapeutic clinical trials in a multi-disciplinary and multi-institutiona model. Scientific strengths include a translational emphasis with biomarker development; pharmacogenomic assessment; genomic assessment and treatment; clinical and tissue imaging; and systems biology. Organizationally, we have formed working groups that leverage scientific expertise and infrastructural strengths from center shared resources to prioritize ET-CTN efforts. Specific niches unique to the WIN-Alliance include strong PK/PD efforts at UWCCC already adding value to CTEP/U01 clinical trials; complementary imaging strengths at UWCCC and CINJ; genomic analysis using the Rutgers University Cell and DNA Repository (RUCDR); and CINJ's relationship with the Institute for Advanced Study's Simons Center for Systems Biology. Over the past five-years UWCCC and CINJ accrued over 4,000 patients on all therapeutic trials, developed 67 center science driven proposals to NCI-CTEP, and accrued a mean of the targeted 100 patients/yr to the UOl supported studies. The specific aims are to: 1) develop and perform early clinical trials with new ET-CTN sponsored anti-cancer agents; 2) leverage and synergize with center programmatic areas of research and cores to translate scientific discoveries from the laboratory into clinical trials; 3) develop integrated and integral genomic, pharmacogenomics, pharmacokinetic, and pharmacodynamic biomarkers; 4) develop integral and integrated novel approaches to clinical and tissue imaging; and, 5) train and develop young investigators in translational research.

描述（由申请人提供）：作为两个 NCI 指定的综合癌症中心，威斯康星大学卡本癌症中心 (UWCCC) 和新泽西州罗格斯癌症研究所 (CINJ) 拥有可靠的领导力和强大的基础设施，以及合作进行临床试验的良好记录。因此，UWCCC 和 CINJ 成立了威斯康星州和新泽西州精密实验治疗联盟 (WIN-Alliance)，其使命是在多学科和多机构模型中开发和评估创新的早期实验治疗临床试验。科学优势包括生物标志物开发的转化重点；药物基因组学评估；基因组评估和治疗；临床和组织成像；和系统生物学。在组织上，我们成立了工作组，利用中心共享资源的科学专业知识和基础设施优势来优先考虑 ET-CTN 工作。 WIN-Alliance 独有的特定领域包括 UWCCC 强大的 PK/PD 努力，已经为 CTEP/U01 临床试验增加了价值； UWCCC 和 CINJ 的成像优势互补；使用罗格斯大学细胞和 DNA 存储库 (RUCDR) 进行基因组分析； CINJ 与高级研究所西蒙斯系统生物学中心的关系。在过去五年中，UWCCC 和 CINJ 在所有治疗试验中积累了 4,000 多名患者，向 NCI-CTEP 制定了 67 项中心科学驱动的提案，并每年为 UOl 支持的研究积累了平均 100 名目标患者。具体目标是：1）利用 ET-CTN 资助的新型抗癌药物开发并进行早期临床试验； 2）利用中心的研究计划领域和核心并与之协同，将实验室的科学发现转化为临床试验； 3) 开发整合的基因组、药物基因组学、药代动力学和药效学生物标志物； 4）开发临床和组织成像的整体和综合新方法； 5) 培训和培养转化研究领域的年轻研究者。